<?xml version="1.0" encoding="UTF-8"?>
<p id="p0185">The management of venous thromboembolism (VTE) and antithrombotic therapy for acute coronary syndromes (ACS) is very crucial in covid-19 pandemic. Anticoagulants like Vitamin K antagonists, dabigatran, apixaban, betrixaban, edoxaban, rivaroxaban and antiplatelets like clopidogrel, prasugrel ticagrelor, cilostazol may have interactions with COVID âˆ’19 investigational drug. Therefore, drug interactions should be kept in mind to mitigate the thrombotic and hemorrhagic events in high-risk patients [
 <xref rid="bb0260" ref-type="bibr">52</xref>].
</p>
